BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a K_i of 6.4 nM for Aβ1-42.

BF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in AD brain. BF-168 is a candidate probe for PET and is found to specifically recognize both neuritic and diffuse plaques, with a K_i of 6.4 nM for Aβ1-42.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Intravenous injection of BF-168 in PS1/APP and APP23 transgenic mice result in specific in vivo labeling to both compact and diffuse amyloid deposits in the brain. In addition, ¹⁸F-radiolabeled BF-168 demonstrates abundant initial brain uptake (3.9% injected dose/gm at 2 min after injection) and fast clearance (t_1/2=24.7 min) after intravenous administration in normal mice. Furthermore, autoradiograms of brain sections from APP23 transgenic mice at 180 min after intravenous injection of [¹⁸F]BF-168 shows selective labeling of brain amyloid deposits with little nonspecific binding.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Intravenous injection of BF-168 in PS1/APP and APP23 transgenic mice result in specific in vivo labeling to both compact and diffuse amyloid deposits in the brain. In addition, ¹⁸F-radiolabeled BF-168 demonstrates abundant initial brain uptake (3.9% injected dose/gm at 2 min after injection) and fast clearance (t_1/2=24.7 min) after intravenous administration in normal mice. Furthermore, autoradiograms of brain sections from APP23 transgenic mice at 180 min after intravenous injection of [¹⁸F]BF-168 shows selective labeling of brain amyloid deposits with little nonspecific binding.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Okamura N, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004 Mar 10;24(10):2535-41.  [Content Brief]